Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L, Fan J, Chong JH, Cesena A, Tam BY, Gilson C, Boykin C, Wang D, Aivazian D, Marcotte D, Xiao G, Le Brazidec JY, Piao J, Lundgren K, Hong K, Vu K, Nguyen K, Gan LS, Silvian L, Ling L, Teng M, Reff M, Takeda N, Timple N, Wang Q, Morena R, Khan S, Zhao S, Li T, Lee WC, Taveras AG, Chao J. Zhang L, et al. Among authors: ling l. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5633-7. doi: 10.1016/j.bmcl.2011.06.129. Epub 2011 Jul 13. Bioorg Med Chem Lett. 2011. PMID: 21798738
Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1.
Le Brazidec JY, Pasis A, Tam B, Boykin C, Black C, Wang D, Claassen G, Chong JH, Chao J, Fan J, Nguyen K, Silvian L, Ling L, Zhang L, Choi M, Teng M, Pathan N, Zhao S, Li T, Taveras A. Le Brazidec JY, et al. Among authors: ling l. Bioorg Med Chem Lett. 2012 Mar 1;22(5):2070-4. doi: 10.1016/j.bmcl.2012.01.019. Epub 2012 Jan 18. Bioorg Med Chem Lett. 2012. PMID: 22326168
Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
Le Brazidec JY, Pasis A, Tam B, Boykin C, Wang D, Marcotte DJ, Claassen G, Chong JH, Chao J, Fan J, Nguyen K, Silvian L, Ling L, Zhang L, Choi M, Teng M, Pathan N, Zhao S, Li T, Taveras A. Le Brazidec JY, et al. Among authors: ling l. Bioorg Med Chem Lett. 2012 Jun 15;22(12):4033-7. doi: 10.1016/j.bmcl.2012.04.085. Epub 2012 Apr 25. Bioorg Med Chem Lett. 2012. PMID: 22607669
Pyrazolone based TGFbetaR1 kinase inhibitors.
Guckian K, Carter MB, Lin EY, Choi M, Sun L, Boriack-Sjodin PA, Chuaqui C, Lane B, Cheung K, Ling L, Lee WC. Guckian K, et al. Among authors: ling l. Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9. doi: 10.1016/j.bmcl.2009.10.108. Epub 2009 Oct 29. Bioorg Med Chem Lett. 2010. PMID: 19914068
2-Aminoimidazoles inhibitors of TGF-beta receptor 1.
Bonafoux D, Chuaqui C, Boriack-Sjodin PA, Fitch C, Hankins G, Josiah S, Black C, Hetu G, Ling L, Lee WC. Bonafoux D, et al. Among authors: ling l. Bioorg Med Chem Lett. 2009 Feb 1;19(3):912-6. doi: 10.1016/j.bmcl.2008.11.119. Epub 2008 Dec 11. Bioorg Med Chem Lett. 2009. PMID: 19135364
SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
Fu K, Corbley MJ, Sun L, Friedman JE, Shan F, Papadatos JL, Costa D, Lutterodt F, Sweigard H, Bowes S, Choi M, Boriack-Sjodin PA, Arduini RM, Sun D, Newman MN, Zhang X, Mead JN, Chuaqui CE, Cheung HK, Zhang X, Cornebise M, Carter MB, Josiah S, Singh J, Lee WC, Gill A, Ling LE. Fu K, et al. Among authors: ling le. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):665-71. doi: 10.1161/ATVBAHA.107.158030. Epub 2008 Jan 17. Arterioscler Thromb Vasc Biol. 2008. PMID: 18202322
2,357 results